A leading Australian healthcare investor is urging peers and governments to provide more support to the country’s medical research sector.
BioScience Managers describes itself as an international healthcare investment firm that funds “innovative science and technology with the potential to transform healthcare”.
“Throughout the pandemic, we have seen Australian biotech and digital health companies step up and work with government and community partners to accelerate innovations and ensure we can deliver key health services across Australia. “said Jeremy Curnock Cook, managing partner.
“However, as a fund manager, including for the Australian Government’s co-investment venture capital program, the Biomedical Translation Fund, we have also continued to see promising Australian companies having to seek the bulk of the capital whose they need to market and grow from overseas, diluting Australian ownership and the benefits to the Australian community and economy.
The company said governments are supporting the development of the sector with investments through the Medical Research Future Fund and co-investment in the construction of new manufacturing facilities.
“We need governments to help us speak out against the Australian private investment community for its lack of understanding and support for the Australian biotech sector and its unrealized potential for patients, community well-being, safety supply chain as well as economic returns and benefits,” Curnock said. To cook.
“Furthermore, there is significant growth potential in emerging digital data and health technologies that are needed to understand system-level issues, target health interventions and spending, drive efficiencies and improve outcomes in areas such as care for the elderly.
“BioScience Managers would like to see Australia’s co-investment venture capital model extended to digital health as part of an integrated, effective and systemic approach to improving health services for Australians.”